Built around research by Stanford scientist Carolyn Bertozzi and MIT researcher Jessica Stark, Valora Therapeutics is ...

Recent health news highlights include WHO's emergency listing of a mpox vaccine, Pfizer's legal setback in recouping ...

Pfizer Inc. (NYSE: PFE) today announced that after a comprehensive internal and external selection process, the company is appointing Chris Boshoff, M.D., PhD, as Chief Scientific Officer and ...

MSD has reported positive topline outcomes from the Phase III study of subcutaneous pembrolizumab in conjunction with ...

The phase 3 MK-3475A-D77 trial tested subcutaneous and intravenous Keytruda given every six weeks in combination with ...

Merck was testing the injectable version of the world's biggest selling drug in a late stage trial of patients with a type of ...

Merck reported promising trial results for a new, easier-to-administer formulation of its blockbuster cancer drug Keytruda. Incyte shares slid after the drug maker paused trial enrollment for a hives ...

Wall Street was mostly higher Tuesday, though the Dow fell triple digits as tensions escalated between Ukraine and Russia ...

JERUSALEM, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ®, ...

US pharma giant Merck & Co (NYSE: MRK) today announced positive top-line results from the pivotal Phase III MK-3475A-D77 ...

Investigational subcutaneous pembrolizumab and berahyaluronidase alfa, in combination with chemotherapy, demonstrates noninferior pharmacokinetics compared to intravenous KEYTRUDA in combination with ...

Merck said on Tuesday a study showed its injectable version of cancer drug Keytruda was not inferior to the currently ...